Dallas, Texas 05/29/2014 (FINANCIALSTRENDS) – Aspens Investment Fund, now the largest shareholder of VIVUS, Inc. (NASDAQ:VVUS), yesterday announced to have acquired approximately 9.65% stake in VIVUS for $46.3 million and is considering to offer a buyout deal for $640 million. The market capitalization of VIVUS Inc. is around $511.30 million. Following the announcement, the stock gained momentum and traded with unusually higher volumes of 19.59 million shares against its 30 day average trading volume of 2.61 million shares. The stock gained nearly 6% during yesterday’s trade and closed at $4.95, recovering from its recent 52-week low of $4.56. Its 52 week high is of $15.62.
Aspen Investment’s Shareholding
Aspen announced that it will discuss with VIVUS, Inc. (NASDAQ:VVUS) about its board membership as well as business strategy. The additional investment, if required, will be financed through working capital of Aspens Investment Fund and pharmaceutical company’s cash plus debt from investment banks.
The recent acquisition by Aspen Investment Funds was of 9.97 million shares of VIVUS including 6.12 million shares underlying forward purchase contracts which will expire in May 2015 and 3.85 million shares underlying exercisable options in July 2014. Aspen said that it is attempting to revive the obesity drug maker, VIVUS which has struggled to effectively penetrate the market with its primary portfolio candidate, Qsymia.
VIVUS, Inc. (NASDAQ:VVUS)’s lead candidate Qsymia was launched in September 2012 and was among the only two obesity drugs approved by the USFDA in more than a decade. However, the company failed to boost the sales of this anti-obesity drug given the prior safety concerns with such drugs, reimbursement problems as well as lack of a major partner for commercialization. The company paid heavy price for this failure as its stock price tumbled from September 2012 high of $25 to the recent price of below $5 per share.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.